Sanofi annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sanofi R&D Spending Growth & History (SAN)
Sanofi's r&d spending was €7.84B for fiscal 2025.
View full Sanofi company overviewSanofi annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €7.84B | €448.0M | +6.06% |
| 2024 | 2024-12-31 | €7.39B | €887.0M | +13.63% |
| 2023 | 2023-12-31 | €6.51B | €6.0M | +0.09% |
| 2022 | 2022-12-31 | €6.50B | €809.0M | +14.21% |
| 2021 | 2021-12-31 | €5.69B | €162.0M | +2.93% |
| 2020 | 2020-12-31 | €5.53B | −€490.0M | −8.14% |
| 2019 | 2019-12-31 | €6.02B | €126.0M | +2.14% |
| 2018 | 2018-12-31 | €5.89B | €422.0M | +7.71% |
| 2017 | 2017-12-31 | €5.47B | €300.0M | +5.80% |
| 2016 | 2016-12-31 | €5.17B | €90.0M | +1.77% |
| 2015 | 2015-12-31 | €5.08B | — | — |
Sanofi quarterly r&d spending
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €2.23B | €324.0M | +16.97% |
| Q1 2026 | 2026-03-31 | €1.75B | — | — |
| Q4 2025 | 2025-12-31 | €2.29B | — | — |
| Q3 2025 | 2025-09-30 | €1.83B | — | — |
| Q2 2025 | 2025-06-30 | €1.91B | — | — |
Sanofi r&d spending trends
Over the last five fiscal years, Sanofi's r&d spending increased from €5.53B to €7.84B, a change of €2.31B. The latest reported quarter, Q2 2026, shows €2.23B.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sanofi source filings ↗